This inventor holds 1 USPTO granted patent. Top assignee: Geneheal Biotechnology Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Wuguang Pan and Research on RUNX2 Down-Regulation.
Introduction
Wuguang Pan is an inventor based in Guangzhou, China. His work includes research into compounds that may reduce RUNX2 expression, a target of interest in cancer research.
Latest Patents
Pan is associated with 1 patent, titled “Application of Compounds in the Preparation of Reagents for Down-Regulation of RUNX2.” The invention describes using fostamatinib, regorafenib, and melatonin as reagents for reducing RUNX2 expression. According to the supplied description, computational studies and disease models indicated that these compounds could significantly down-regulate RUNX2 and may have targeted therapeutic potential for cancers with abnormally high RUNX2 expression. The disclosure also highlights their potential use as laboratory reagents.
Career Highlights
Pan is associated with Geneheal Biotechnology Co., Ltd. His patent work focuses on compounds and their potential applications in biomedical research.
Collaborations
Wei Zhu is identified as Pan’s coworker. The supplied information does not specify their particular roles or contributions to the patent.
Conclusion
Wuguang Pan’s documented invention explores compounds for down-regulating RUNX2, connecting his work with laboratory research and potential cancer-treatment applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile